Relmada Soars on Cancer Data, $160M Boost Ahead of Key Conference

CORAL GABLES, Fla. – March 09, 2026 – Relmada Therapeutics (Nasdaq: RLMD) ignited investor enthusiasm Monday, with its stock surging over 40% following a dual announcement of highly promising clinical trial data for its lead cancer drug and a substantial $160 million capital raise. The news provides a powerful tailwind for the company's leadership as they head into a pivotal presentation at the Leerink Partners Global Healthcare Conference this week.

The clinical-stage biotechnology company, which focuses on oncology and central nervous system (CNS) disorders, saw its shares hit a new 52-week high of $7.05 in early trading. The market's powerful reaction underscores the significance of the developments, which position Relmada to advance its most promising asset into late-stage trials and secure its financial footing for years to come.

A Breakthrough in Bladder Cancer Treatment

The primary catalyst for the stock's dramatic ascent was the release of positive 12-month interim data from the ongoing Phase 2 trial of NDV-01. The drug is an intravesical therapy being evaluated in patients with high-risk non-muscle invasive bladder cancer (NMIBC), a condition where treatment options are limited and the risk of progression is a serious concern.

The results exceeded expectations. The trial demonstrated a 12-month complete response (CR) rate of 76% across the entire high-risk NMIBC patient group. More impressively, within the notoriously difficult-to-treat subgroup of patients whose cancer is unresponsive to the standard Bacillus Calmette-Guérin (BCG) therapy, NDV-01 achieved an 80% CR rate at the one-year mark. This specific patient population represents a significant unmet medical need, and such a high response rate is a major clinical signal.

Adding to the positive clinical profile, the therapy was well-tolerated. Relmada reported a favorable safety profile with no treatment-related adverse events of Grade 3 or higher and, critically, no discontinuations due to side effects. Furthermore, no patients in the trial experienced progression to more dangerous muscle-invasive disease or required a radical cystectomy—the surgical removal of the bladder.

These robust findings provide a strong foundation for the company to move forward. Relmada confirmed that the U.S. Food and Drug Administration (FDA) has aligned on a path forward, and the company plans to initiate its Phase 3 registrational program, dubbed RESCUE, by the middle of 2026. The program will pursue two distinct pathways, targeting both second-line BCG-unresponsive NMIBC and its use as an adjuvant therapy for intermediate-risk NMIBC. The market potential is significant, with some analysts having previously projected peak sales for NDV-01 could reach $2.3 billion.

Fortifying the Future with a $160 Million War Chest

Complementing the clinical success, Relmada announced the closing of an oversubscribed private investment in public equity (PIPE) financing, securing approximately $160 million in gross proceeds. The deal, which involves the sale of common stock and pre-funded warrants, is a resounding vote of confidence from sophisticated healthcare investors.

The financing was led by a syndicate of top-tier institutional investors, including Venrock Healthcare Capital Partners, RA Capital Management, and OrbiMed. The participation of such prominent firms is widely seen as a strong validation of the company’s technology and strategic direction. The capital injection is transformative for the clinical-stage company, which currently generates no revenue.

This funding extends Relmada's cash runway well into 2028, effectively de-risking its financial position and providing ample resources to execute its ambitious clinical plans. The proceeds are earmarked for advancing the company's research and development programs, including the costly but crucial Phase 3 RESCUE trial for NDV-01, as well as for working capital and general corporate purposes.

The Investor Spotlight at Leerink Partners

The timing of these announcements could not be more strategic. Relmada's Chief Executive Officer, Sergio Traversa, and Chief Financial Officer, Maged Shenouda, are scheduled to present a fireside chat at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10. The conference is a premier event for the healthcare industry, attracting a concentrated audience of investors, analysts, and potential partners.

With a major clinical win and a fortified balance sheet, the executive team will step onto the stage with significant momentum. The presentation, along with a series of one-on-one investor meetings, provides a critical platform to elaborate on the NDV-01 data, outline the design and timeline for the Phase 3 program, and articulate the company's long-term vision. Investors will be keen to understand how management plans to deploy its new capital to maximize the value of its pipeline. The fact that Leerink Partners, the conference host, also acted as a placement agent for the financing highlights the deeply integrated nature of these industry events in shaping a company's trajectory.

A Diversified Pipeline Beyond Oncology

While NDV-01 is currently the star of the show, the conference will also be an opportunity for Relmada to remind the investment community of the breadth of its pipeline. The company maintains a dual focus on both oncology and CNS disorders, a strategy that offers multiple avenues for growth and diversification.

In its CNS portfolio, Relmada is advancing sepranolone, a neurosteroid described as "Phase 2b-ready." This candidate is being developed for a range of conditions related to excessive GABAergic activity, including Prader-Willi Syndrome, Tourette Syndrome, and excessive tremor. Some financial reports have also highlighted esmethadone (REL-1017), an NMDA receptor antagonist, as a key product candidate being developed for depression and other CNS indications.

Further showcasing its innovative approach, the company has also completed a Phase 1 safety study for REL-P11, a modified-release formulation of psilocybin intended for the treatment of metabolic disease. This diversified pipeline, spanning multiple therapeutic areas with high unmet needs, forms a core part of the company's value proposition that management will likely emphasize to investors looking for long-term growth potential.

With a consensus "Strong Buy" rating from analysts and price targets suggesting further upside, the market has clearly validated Relmada's recent progress. The upcoming fireside chat will be closely watched, not just as a victory lap for its recent successes, but as a crucial window into the execution strategy that will carry the company through its next phase of late-stage development.